
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML

Alpha Trial Link:

<https://clinicaltrials.gov/ct2/show/NCT03301597>

Alpha Clinic (primary):

UC Davis

Contact:

Name:

Jane McCluskey

Phone:

916-703-9302

Email:

jmccluskey@ucdavis.edu

Alpha Trial Sponsor:

Nohla Therapeutics

Disease Indication:

Cancer – Leukemia

Enrollment Status:

Recruiting

Source URL: <https://www.cirm.ca.gov/alphaclinictrial/phase-2-open-label-multi-center-randomized-controlled-dose-finding-study-safety-and>